# Pharmadax Genesis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmadax-genesis

- Industry: Pharmaceuticals
- Headquarters: Jiaxing, China
- Total disclosed funding: $28M
- Latest round: Series A (Dec 9, 2024)
- Investors on record: 3

## About

Established in 2016 and based in Jiaxing, China, Pharmadax Genesis operates as a drug R&D CRO (Contract Research Organization) focuses on providing radioactive therapeutic drugs. In December 2024, Pharmadax Genesis closed a series A2 funding led by new investor China National Nuclear Corporation Capital.

The company mainly provides innovative drugs in nuclear medicine. Nuclear drug products include diagnostic drugs and therapeutic drugs. It has more than ten product pipelines, among which PMD11 and PMD12 are radioactive therapeutic drugs. Pharmadax Genesis also provides molecular imaging diagnosis. It has PharmadaX®? target molecule screening and targeted radiolabelled platform, and PharmadaX®? platform that combines proximal therapy and immunotherapy. 

The company generates revenue by providing molecular imaging diagnosis and innovative drugs in nuclear medicine.

The company will use the funds for the research and development of existing pipelines and the construction of a radioactive drug industrialization base. The company expects to launch 6 to 8 new pipeline products between the end of 2024 and the first half of 2025, and will optimize its R&D platform in the next two to three years to build a full range of target molecule R&D capabilities. It also expects to complete the first phase of plant infrastructure construction by the end of 2025.

## Funding rounds

- Series A, Dec 9, 2024, $14M — China National Nuclear Corporation Capital
- Series A, May 11, 2024, $14M — Caitong Capital, Cloudview Capital

## Investors

- Caitong Capital (https://capitalatlas.ai/funds/caitong-capital) — Series A
- Cloudview Capital (https://capitalatlas.ai/funds/cloudview-capital) — Series A
- China National Nuclear Corporation Capital — Series A